Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1006578 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY1006578 | DRUG | Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET |
Inclusion Criteria: * All: * Males or females aged \>/- 50 years * Participants must be able to understand the information provided on purpose and conduct of the clinical study, must be capable of giving fully informed consent in writing, and have read and signed the informed consent prior to ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Hologic, Inc. | HOLX | 1 | N/A | Undisclosed |
| Intelligent Bio Solutions Inc. | INBS | 1 | - | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
| GE Healthcare Technologies Inc. | GEHC | 2 | N/A | Undisclosed |
BAY1006578 is an investigational small molecule being developed for diagnostic imaging. It was evaluated in a Phase 1 clinical trial for its diagnostic potential in probable Alzheimer's disease patients compared to healthy volunteers, as well as for radiation dosimetry in healthy volunteers.
BAY1006578 is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker LNTH. The drug is currently in Phase 1 clinical development as an investigational diagnostic imaging agent.
BAY1006578 is in Phase 1 clinical development. It is an investigational drug and is not approved by the FDA. One Phase 1 trial has been completed, and there are no active or ongoing trials for this asset at this time.
BAY1006578 has one completed clinical trial, registered as NCT01153607. This Phase 1 study evaluated the diagnostic potential of BAY1006578 in probable Alzheimer's disease patients versus healthy volunteers and assessed radiation dosimetry in healthy volunteers. The trial enrolled 24 participants in Finland and Sweden.
BAY1006578 is the primary name for this investigational diagnostic imaging agent. No alternative names have been reported for this compound in the available clinical trial information.